CTLA4 and metastatic melanoma: In contrast, results of the phase 3 study (MDX010–20) leading to the approval of ipilimumab (anti-CTLA4) for the treatment of metastatic melanoma demonstrated clinical response rate in 11% (CR – 1.5%; PR – 9.5%) of patients, with DC rate of 28.5%.